Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

IMRX EBITDA Margin

EBITDA as a percentage of revenue.

Immuneering CorporationNASDAQ: IMRX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2022
-16238.4%
Year-over-year change
-14619.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IMRX compares with its peers on the latest reported figures

IMRX Competitors Peer median
EBITDA Margin for IMRX and competitors
Company Period LTM level YoY 3-year change
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
PYXSPyxis Oncology, Inc.LTM Mar 2026-547.9% ——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-2873.3% -2889.4 pp—
HUMAHumacyte, Inc.LTM Mar 2026-3956.7% -3182.9 pp-1247.4 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
IMRXImmuneering CorporationFY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
ZURAZura Bio LimitedFY2025— ——
Peer median (excluding IMRX) -402.5%-16.4 pp-35.4 pp

Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.08M316.95K000
Cost of Revenue1.15M158.12K00698.89K
Gross Profit926.89K158.83K00(698.89K)
Gross Margin44.6%50.1%———
Research & Development26.54M36.27M41.62M47.96M42.05M
Selling, General & Admin8.27M15.61M16.76M16.08M17.3M
Operating Expenses34.81M51.9M58.41M64.07M58.68M
Depreciation & Amortization159.07K277.25K352.08K385.07K698.89K
EBITDA(33.68M)(51.47M)(58.06M)(63.69M)(55.33M)
EBITDA Margin-1619.5%-16238.4%———
Operating Income(33.89M)(51.74M)(58.41M)(64.07M)(59.38M)
Operating Margin-1629.2%-16325.8%———
Interest Income169.9K1.01M3.61M2.59M3.04M
Interest Expense00000
Other Income / Expenses42.83K1.23M4.94M3.03M3.35M
Income Before Tax(33.84M)(50.51M)(53.47M)(61.04M)(56.02M)
Pre-Tax Margin-1627.1%-15937.4%———
Income Tax Expense(307.49K)0000
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Net Margin-1612.3%-15937.3%———
EPS (Basic)(1.27)(1.87)(1.88)(2.04)(1.27)
EPS (Diluted)(1.27)(1.87)(1.88)(2.04)(1.27)
Weighted Avg Shares26.32M26.39M28.42M29.98M44.01M
Weighted Avg Shares (Diluted)26.32M26.39M28.42M29.98M44.01M

Immuneering Corporation

NASDAQ:IMRX

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.